Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.25.3
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Product Information [Line Items]        
Total net revenue $ 1,446,066 $ 2,350,386 $ 4,569,146 $ 7,154,429
Health Care, Patient Service [Member]        
Product Information [Line Items]        
Total net revenue [1] 1,172,948 2,049,851 3,685,397 6,259,806
Histology Service Fees [Member]        
Product Information [Line Items]        
Total net revenue 255,586 281,861 827,944 811,914
Medical Director Fees [Member]        
Product Information [Line Items]        
Total net revenue 17,274 16,943 51,171 50,136
Department Of Defense Observational Studies [Member]        
Product Information [Line Items]        
Total net revenue 1,731 8,654
Other Revenues [Member]        
Product Information [Line Items]        
Total net revenue $ 258 $ 4,634 $ 23,919
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $619,000 and $332,000 for the nine months ended September 30, 2025 and 2024, respectively, and $296,000 and $133,000 for the three months ended September 30, 2025 and 2024, respectively.